Market Research Report

A quick peek into the report

1.1 Inclusion and Exclusion

2.1 Scope of Work
2.2 Key Questions Answered in the Report

3.1 U.S. Hematologic Malignancies Testing Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

5.1 Midwest U.S.
5.2 Mid Atlantic
5.3 The Southwest
5.4 New England
5.5 The West
5.6 The South

6.1 Market Drivers
6.1.1 Rising Incidence of Hematologic Malignancies
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
6.1.3 Favorable Reimbursement Scenario in the U.S. hematologic Malignancies Testing Market
6.1.4 Increase in Funding in Hematologic Malignancies Testing Market
6.2 Restraints
6.2.1 High Pricing Pressure
6.2.2 Lack of Trained Professionals
6.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers
6.3 U.S. Market Opportunities
6.3.1 An Underlying Relaxation in Revised 2018 PAMA Criteria
6.3.2 Informatics and Technological Innovation for Larger Consumer Base
6.3.3 Technological Advancements in the Field of Molecular Diagnostics

7.1 Key Strategies and Developments
7.1.1 Synergistic Activities
7.1.2 Approvals
7.1.3 Product Launches and Enhancements
7.1.4 Merger, Acquisitions & Expansions
7.2 Product Scenario
7.3 Funding Scenario
7.4 Market Share Analysis
7.5 Growth Share Analysis (Opportunity Mapping)
7.5.1 By Company
7.5.2 By Product

8.1 Regulatory Framework
8.1.1 Legal Requirements and Framework in the U.S.
8.2 Reimbursement Scenario
8.2.1 Protecting Access to Medicare Act (PAMA) Criteria for Advanced Diagnostic Laboratory Tests (ADLT)
8.3 Physicians’ Perceptions

9.1 Services
9.2 Kits
9.2.1 NGS-Based Gene Panels
9.2.1.1 Leukemia
9.2.1.2 Lymphoma
9.2.1.3 Multiple Myeloma
9.2.1.4 Myeloproliferative Neoplasms
9.2.1.5 Myelodysplastic Syndromes
9.2.2 NGS-Based Molecular Clonality Testing
9.2.2.1 Leukemia
9.2.2.2 Lymphoma
9.2.2.3 Multiple Myeloma
9.2.2.4 Myeloproliferative Neoplasms
9.2.2.5 Myelodysplastic Syndromes
9.2.3 NGS-Based Translocation Testing
9.2.3.1 Leukemia
9.2.3.2 Lymphoma
9.2.3.3 Multiple Myeloma
9.2.3.4 Myeloproliferative Neoplasms
9.2.3.5 Myelodysplastic Syndromes
9.2.4 NGS-Based Mutation Testing
9.2.4.1 Leukemia
9.2.4.2 Lymphoma
9.2.4.3 Multiple Myeloma
9.2.4.4 Myeloproliferative Neoplasms
9.2.4.5 Myelodysplastic Syndromes
9.2.5 NGS-Based Minimal Residual Disease (MRD) Testing
9.2.5.1 Leukemia
9.2.5.2 Lymphoma
9.2.5.3 Multiple Myeloma
9.2.5.4 Myeloproliferative Neoplasms
9.2.5.5 Myelodysplastic Syndromes

10.1 Specialty Clinics and Hospitals
10.2 Diagnostic Laboratories
10.3 Reference Laboratories
10.4 Research Institutions

11.1 Leukemia
11.2 Lymphoma
11.3 Multiple Myeloma
11.4 Myeloproliferative Neoplasms
11.5 Myelodysplastic Syndromes

12.1 Next-generation Sequencing (NGS)
12.2 Polymerase Chain Reaction (PCR)
12.3 Fluorescence In-Situ Hybridization (FISH)
12.4 Immunohistochemistry (IHC)
12.5 Flow Cytometry
12.6 Other Technologies

13.1 Overview
13.2 Abbott Laboratories
13.2.1 Company Overview
13.2.2 Role of Abbott Laboratories in the U.S. Hematologic Malignancies Testing Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 Illumina, Inc.
13.3.1 Company Overview
13.3.2 Role of Illumina, Inc. in the U.S. Hematologic Malignancies Testing Market
13.3.3 Financials
13.3.4 Key Insights About Financial Health of the Company
13.3.5 SWOT Analysis
13.4 F. Hoffmann-La Roche Ltd
13.4.1 Company Overview
13.4.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Hematologic Malignancies Testing Market
13.4.3 Financials
13.4.4 Key Insights About Financial Health of the Company
13.4.5 SWOT Analysis
13.5 Bio-Rad Laboratories, Inc.
13.5.1 Company Overview
13.5.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Hematologic Malignancies Testing Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Sysmex Corporation
13.6.1 Company Overview
13.6.2 Role of Sysmex Corporation in the U.S. hematologic Malignancies Testing Market
13.6.3 Financials
13.6.4 Key Insights About Financial Health of the Company
13.6.5 SWOT Analysis
13.7 ASURAGEN, INC.
13.7.1 Company Overview
13.7.2 Role of ASURAGEN, INC. in the U.S. Hematologic Malignancies Testing Market
13.7.3 SWOT Analysis
13.8 Cancer Genetics Inc.
13.8.1 Company Overview
13.8.2 Role of Cancer Genetics Inc.in the U.S. Hematologic Malignancies Testing Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 QIAGEN N.V.
13.9.1 Company Overview
13.9.2 Role of QIAGEN N.V. in the U.S. Hematologic Malignancies Testing Market
13.9.3 Financials
13.9.4 Key Insights about Financial Health of the Company
13.9.5 SWOT Analysis
13.10 ArcherDX, Inc.
13.10.1 Company Overview
13.10.2 Role of ArcherDX, Inc. in the U.S. Hematologic Malignancies Testing Market
13.10.3 SWOT Analysis
13.11 Adaptive Biotechnologies
13.11.1 Company Overview
13.11.2 Role of Adaptive Biotechnologies in the U.S. Hematologic Malignancies Testing Market
13.11.3 SWOT Analysis
13.12 ICON plc
13.12.1 Company Overview
13.12.2 Role of ICON plc in the U.S. Hematologic Malignancies Testing Market
13.12.3 Financials
13.12.4 SWOT Analysis
13.13 Quest Diagnostics Incorporated
13.13.1 Company Overview
13.13.2 Role of Quest Diagnostics Limited in the U.S. Hematologic Malignancies Testing Market
13.13.3 Financials
13.13.4 SWOT Analysis
13.14 ARUP Laboratories
13.14.1 Company Overview
13.14.2 Role of ARUP Laboratories in the U.S. Hematologic Malignancies Testing Market
13.14.3 SWOT Analysis
13.15 Invivoscribe, Inc.
13.15.1 Company Overview
13.15.2 Role of Invivoscribe, Inc. in the U.S. Hematologic Malignancies Testing Market
13.15.3 SWOT Analysis
13.16 NeoGenomics Laboratories, Inc.
13.16.1 Company Overview
13.16.2 Role of NeoGenomics Laboratories, Inc. in the U.S. hematologic malignancies testing Market
13.16.3 Financials
13.16.4 Key Insights about Financial Health of the Company
13.16.5 SWOT Analysis
13.17 Invitae Corporation
13.17.1 Company Overview
13.17.2 Role of Invitae Corporation, Inc. in the U.S. hematologic malignancies testing Market
13.17.3 Financials
13.17.4 Key Insights about Financial Health of the Company
13.17.5 SWOT Analysis
13.18 Opko Health
13.18.1 Company Overview
13.18.2 Role of Opko Health, Inc. in the U.S. hematologic malignancies testing Market
13.18.3 Financials
13.18.4 Key Insights about Financial Health of the Company
13.18.5 SWOT Analysis
13.19 Laboratory Corporation of America Holdings
13.19.1 Company Overview
13.19.2 Role of Laboratory Corporation of America Holdings in the U.S. Hematologic Malignancies Market
13.19.3 Financials
13.19.4 SWOT Analysis

Table 7.1: Market Players with Key Product Listing
Table 8.1: Reimbursement Coverage
Table 8.2: Key Coverage Providers for Hematologic Malignancies Testing
Table 9.1: Product Portfolio: NGS-Based Gene Panels
Table 9.2: Product Portfolio: NGS-Based Molecular Clonality Testing
Table 9.3: Product Portfolio: NGS-Based Translocation Testing
Table 9.4: Product Portfolio: NGS-Based Mutation Testing
Table 9.5: Product Portfolio: NGS-Based Minimal Residual Disease
Table 13.1: Quest Diagnostics Incorporated Product Portfolio
Table 13.2: Competitive Portfolio of Opko Health OnkoSight with Other Standard Counterparts in the U.S. hematologic Malignancies Market

Figure 1: Estimated New Cases of Hematologic Malignancies in 2020
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the U.S. Hematologic Testing Market
Figure 3: Key Strategies Incorporated by Stakeholders of U.S. Hematologic Testing Market to Sustain the Competition (from January 2016 to December 2019)
Figure 4: Dominating Segments of the U.S. Hematologic Malignancies Testing Market, 2019 and 2025
Figure 5: U.S. Hematologic Malignancies Testing (by Product), 2019 and 2025
Figure 6: NGS Based U.S. Hematologic Malignancies Testing (by Product), 2019 and 2025
Figure 7: U.S. Hematologic Malignancies Testing Market (by Technology), 2019 and 2025
Figure 8: U.S. Hematologic Malignancies Testing Market (by End-User, 2019 and 2025)
Figure 2.1: U.S. Hematologic Malignancies Testing Market Segmentation
Figure 3.1: U.S. Hematologic Malignancies Testing Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Relative Percent of New Hematological Malignancies Expected to be Reported in U.S. in 2020
Figure 4.2: Relative Percent of New Cases Lymphomas Expected in U.S. in 2020
Figure 4.3: Relative Percent of New Cases of Leukemias in U.S. in 2020
Figure 4.4: Prevalence of Different Hematological Malignancies across U.S. ( 2013-2017)
Figure 4.5: State Specfic Prevalence of of Leukemia Across Major U.S. States (2017)
Figure 4.6: State Specfic Prevalence of Non-Hodgkin’s Lymphoma Across Major U.S. States (2017)
Figure 5.1: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukaemia in Midwest U.S. (2017)
Figure 5.2: Midwest U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.3: Midwest U.S. Hematologic Malignancies Testing Market Size by State (U.S. $ Mn) 2019
Figure 5.4: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in Mid-Atlantic U.S. (2017)
Figure 5.5: Mid-Atlantic Hematology Malignancies Testing Market Volume by State (2019)
Figure 5.6: Mid Atlantic Hematology Malignancies Testing Market Size by State (U.S. $Mn) (2019)
Figure 5.7: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in Southwest U.S. by State (2017)
Figure 5.8: Southwest U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.9: Southwest U.S. Hematologic Malignancies Testing Market Size by State ($ Mn) 2019
Figure 5.10: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in New England, by State (2017)
Figure 5.11: New England Hematology Malignancies Testing Volume by State, 2019
Figure 5.12: New England Hematology Malignancies Testing Market Size by State ($Mn) 2019
Figure 5.13: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in the West U.S. (2017)
Figure 5.14: The West U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.15: West U.S. Hematologic Malignancies Testing Market Size by State (USD Mn) 2019
Figure 5.16: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in the South U.S. (2017)
Figure 5.17: South U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.18: South U.S. Hematologic Malignancies Testing Market Size by State ($ Mn) 2019
Figure 6.1: Market Dynamics of U.S. Hematologic Malignancies Testing Market
Figure 6.2: Leukemia, U.S. Incident Cases (x1000), (2010-2018)
Figure 7.1: Share of Key Developments and Strategies, January 2016 – September 2019
Figure 7.2: Synergistic Activities Share (by Companies), January 2016 – September 2019
Figure 7.3: Approvals Share (by Companies), January 2016 – September 2019
Figure 7.4: Product Launches and Enhancements Share (by Companies), January 2016 – September 2019
Figure 7.5: Acquisition and Merger Share (by Companies), January 2016 – September 2019
Figure 7.6: Market Share Analysis for the U.S. Hematologic Malignancies Testing Market, 2018
Figure 7.7: Growth Share Matrix for U.S. Hematologic Malignancies Testing Market (by company), 2018
Figure 7.8: Growth Share Matrix for U.S. Hematologic Malignancies Testing Market (by Product), 2018
Figure 8.1: ADLT Parameters
Figure 9.1: U.S. Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
Figure 9.2: U.S. NGS-Based Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
Figure 9.3: U.S. Hematologic Malignancies Testing Services Market, $Million, 2018-2025
Figure 9.4: U.S. NGS-Based Hematologic Malignancies Testing Services Market, $Million, 2018-2025
Figure 9.5: U.S. Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
Figure 9.6: U.S. NGS Based Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
Figure 9.7: Gene Panels Market, $Million, 2018-2025
Figure 9.8: NGS-Based Gene Panels Leukemia Market, $Million, 2018-2025
Figure 9.9: NGS-Based Gene Panels Lymphoma Testing Market, $Million, 2018-2025
Figure 9.10: NGS-Based Gene Panels Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.11: NGS-Based Gene Panels Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.12: NGS-Based Gene Panels Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.13: NGS-Based Molecular Clonality Testing Market, $Million, 2018-2025
Figure 9.14: NGS-Based Molecular Clonality Leukemia Testing Market, $Million, 2018-2025
Figure 9.15: NGS-Based Molecular Clonality Lymphoma Testing Market, $Million, 2018-2025
Figure 9.16: NGS-Based Molecular Clonality Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.17: NGS-Based Molecular Clonality Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.18: NGS-Based Molecular Clonality Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.19: NGS-Based Translocation Testing Market, $Million, 2018-2025
Figure 9.20: NGS-Based Translocation Leukemia Testing Market, $Million, 2018-2025
Figure 9.21: NGS-Based Translocation Lymphoma Testing Market, $Million, 2018-2025
Figure 9.22: NGS-Based Molecular Clonality Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.23: NGS-Based Translocation Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.24: NGS-Based Translocation Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.25: NGS-Based Mutation Testing Market, $Million, 2018-2025
Figure 9.26: NGS-Based Mutation Leukemia Testing Market, $Million, 2018-2025
Figure 9.27: NGS-Based Mutation Lymphoma Testing Market, $Million, 2018-2025
Figure 9.28: NGS-Based Mutation Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.29: NGS-Based Mutation Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.30: NGS-Based Mutation Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.31: NGS-Based Minimal Residual Disease (MRD) Testing Market, $Million, 2018-2025
Figure 9.32: NGS-Based MRD Leukemia Market, $Million, 2018-2025
Figure 9.33: NGS-Based Translocation Lymphoma Testing Market, $Million, 2018-2025
Figure 9.34: NGS-Based Minimal Residual Disease Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.35: NGS-Based Minimal Residual Disease Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.36: NGS-Based Minimal Residual Disease Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 10.1: U.S. Hematologic Malignancies Testing Market (by End User), 2019 vs 2025
Figure 10.2: Specialty Clinics and Hospitals Market, $Million, 2018-2025
Figure 10.3: Diagnostic Laboratories Market, $Million, 2018-2025
Figure 10.4: Reference Laboratories Market, $Million, 2018-2025
Figure 10.5: Research Institutions Market, $Million, 2018-2025
Figure 11.1: U.S. Hematologic Malignancies Testing Market (by Disease), 2019 vs 2025
Figure 11.2: U.S. Leukemia Testing Market, $Million, 2018-2025
Figure 11.3: U.S. Lymphoma Testing Market, $Million, 2018-2025
Figure 11.4: U.S. Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 11.5: U.S. Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 11.6: U.S. Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 12.1: U.S. Hematologic Malignancies Testing Market (by Technology), 2019 vs 2025
Figure 12.2: U.S. Hematologic Malignancies Testing Market by NGS, $Million, 2018-2025
Figure 12.3: U.S. Hematologic Malignancies Testing Market by PCR, $Million, 2018-2025
Figure 12.4: U.S. Hematologic Malignancies Testing Market by FISH, $Million, 2018-2025
Figure 12.5: U.S. Hematologic Malignancies Testing Market by Immunohistochemistry, $Million, 2018-2025
Figure 12.6: U.S. Hematologic Malignancies Testing Market by Flow Cytometry, $Million, 2018-2025
Figure 12.7: U.S. Hematologic Malignancies Testing Market by Other Technologies, $Million, 2018-2025
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Abbott Laboratories: Overall Product Portfolio
Figure 13.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 13.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 13.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 13.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 13.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 13.8: Abbott Laboratories: SWOT Analysis
Figure 13.9: Illumina, Inc.: Overall Product Portfolio
Figure 13.10: Illumina, Inc.: Overall Financials, 2017-2019
Figure 13.11: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 13.12: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 13.13: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 13.14: Illumina, Inc.: SWOT Analysis
Figure 13.15: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 13.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 13.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 13.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.20: F. Hoffmann-La Roche: SWOT Analysis
Figure 13.21: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 13.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 13.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 13.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 13.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 13.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 13.27: Sysmex Corporation: Overall Product Portfolio
Figure 13.28: Sysmex Corporation: Overall Financials, 2016-2018
Figure 13.29: Sysmex Corporation: Sales (by Segment), 2016-2018
Figure 13.30: Sysmex Corporation: Sales (by Region), 2016-2018
Figure 13.31: Sysmex Corporation: R&D Expenditure, 2016-2018
Figure 13.32: Sysmex Corporation: SWOT Analysis
Figure 13.33: ASURAGEN, INC.: Overall Product Portfolio
Figure 13.34: ASURAGEN, INC.: SWOT Analysis
Figure 13.35: Product Portfolio: Cancer Genetics Inc.
Figure 13.36: Cancer Genetics Inc.: Overall Financials, 2016-2018
Figure 13.37: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
Figure 13.38: Cancer Genetics Inc.: Sales (by Region), 2016-2018
Figure 13.39: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
Figure 13.40: Cancer Genetics Inc.: SWOT Analysis
Figure 13.41: QIAGEN N.V.: Overall Product Portfolio
Figure 13.42: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 13.43: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 13.44: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 13.45: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 13.46: QIAGEN N.V.: SWOT Analysis
Figure 13.47: ArcherDX, Inc.: Overall Product Portfolio
Figure 13.48: ArcherDX, Inc.: SWOT Analysis
Figure 13.49: Adaptive Biotechnologies: Overall Product Portfolio
Figure 13.50: Adaptive Biotechnologies: SWOT Analysis
Figure 13.51: ICON plc: Overall Product Portfolio
Figure 13.52: ICON plc: Overall Financials, 2016-2018
Figure 13.53: ICON plc: Revenue (by Region), 2016-2018
Figure 13.54: ICON plc: SWOT Analysis
Figure 13.55: Quest Diagnostics Incorporated: Overall Product Portfolio
Figure 13.56: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 13.57: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2016 - 2018
Figure 13.58: Quest Diagnostics Incorporated: SWOT Analysis
Figure 13.59: ARUP Laboratories: Overall Product Portfolio
Figure 13.60: ARUP Laboratories: SWOT Analysis
Figure 13.61: Invivoscribe, Inc.: Overall Product Portfolio
Figure 13.62: Invivoscribe, Inc.: SWOT Analysis
Figure 13.63: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
Figure 13.64: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
Figure 13.65: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 13.66: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 13.67: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 13.68: Invitae Corporation: Overall Product Portfolio
Figure 13.69: Invitae Corporation: Overall Financials, 2016-2018
Figure 13.70: Invitae Corporation: Revenue (by Segment), 2016-2018
Figure 13.71: Invitae Corporation: Revenue (by Geography), 2016-2018
Figure 13.72: Invitae Corporation: R&D Expenditure, 2016-2018
Figure 13.73: Invitae Corporation: SWOT Analysis
Figure 13.74: Opko Health: Overall Services Portfolio
Figure 13.75: Opko Health: Overall Financials, 2016-2018
Figure 13.76: Opko Health: Revenue (by Segment), 2016-2018
Figure 13.77: Opko Health: R&D Expenditure, 2016-2018
Figure 13.78: Opko Health: SWOT Analysis
Figure 13.79: Laboratory Corporation of America Holdings: Overall Services Portfolio
Figure 13.80: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 13.81: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 13.82: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 13.83: Laboratory Corporation of America Holdings: SWOT Analysis

Market Overview

U.S. Hematologic Malignancies Market Forecast

The U.S. hematologic malignancies market analysis by BIS Research projects the market to grow at a significant CAGR of 14.60% during the forecast period, 2019-2025. The U.S. hematologic malignancies market generated $723.9 million revenue in 2018, in terms of value.

The U.S. hematologic malignancies market growth has been primarily attributed to the major drivers in this market, such as rising incidence of hematologic malignancies, favorable reimbursement scenario, and increase in funding in the hematologic malignancies market. However, there are factors hindering the growth of the market, such as lack of training professionals, high pricing pressure, and issue pertaining to the analytic validity of genetic testing.

Expert Quote

“In an era of precision and increasingly personalized therapy, the healthcare industry demands cost-effective options that can robustly identify biomarkers to help select cancer patients most likely to benefit from the emerging class of immuno-oncology drug.”

Key Questions Answered in this Report:

•   What are the major market drivers, challenges, and opportunities in the U.S. hematologic malignancies testing market?
•   What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
•   Which is the dominant product type developed by the leading and emerging players for the diagnosis of hematologic malignancies?
•   What are the key technologies that have been used by leading players in the U.S. market for the development of diagnostic solutions for hematologic malignancies?
•   How each segment of the market is expected to grow during the forecast period from 2019 to 2025 based on:
o   product type
o   disease
o   technology
o   end user
o   country, i.e., U.S.
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the reimbursement scenario and the regulations for the development of diagnostic solutions for the diagnosis of hematologic malignancies, specifically in the U.S.?

Report Description

Scope of the Market Intelligence on the U.S. Hematologic Malignancies Market

The U.S. hematologic malignancies market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with industrial and biological research. In addition, the study also includes exhaustive information on unmet needs, perception on new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the U.S. hematologic malignancies market.

Market Segmentation

The U.S. hematologic malignancies market (on the basis of product type) is segmented into kits and services.

The U.S. hematologic malignancies market (on the basis of technology) is segmented into polymerase chain reaction, next-generation sequencing, fluorescence in-situ hybridization, immunohistochemistry, flow-cytometry, and other technologies.

The U.S. hematologic malignancies market (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.

The U.S. hematologic malignancies market (on the basis of end user) is segmented into specialty clinics and hospitals, research institutions, reference laboratories, diagnostic laboratories, and other end users.

Key Companies in the U.S. Hematologic Malignancies Market

The key manufacturers that have been contributing significantly to the U.S. hematologic malignancies market includes Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Corporation, Cancer Genetics Inc., QIAGEN N.V., ICON plc, Quest Diagnostics Incorporated, Invitae Corporation, Opkp Health, Laboratory Corporation of American Holdings, NeoGenomics Laboratories, Inc., ASURAGEN, INC., ArcherDX, Inc., Adaptive Biotechnologies, ARUP Laboratories, and Invivoscribe, Inc, among others.